Can immune cells revive lung cancer treatment?
NCT ID NCT07498595
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining a patient's own immune cells (called TILs) with a targeted therapy drug can safely treat advanced lung cancer that has stopped responding to standard targeted treatment. Researchers will enroll 50 adults with EGFR-mutant non-small cell lung cancer. The main goal is to check for side effects, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tumor-infiltrating lymphocytes (TILs) combined with a third-generation EGFR-TKI
What this could lead to
If it works, this could point toward a new treatment option for people with advanced lung cancer whose tumors have stopped responding to targeted therapy.
What could go wrong
This is a very early, small safety study (50 people) and may not show clear benefit. The treatment involves surgery to collect immune cells and carries risks like infection or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.